Laser Hair Growth Helmet FAQs

Low-level laser therapy (LLLT), also known as photobiomodulation, has been studied as a non-invasive treatment for androgenetic alopecia, or pattern hair loss. Clinical studies have reported improvements in hair density or hair counts in some men and women when LLLT is used consistently. Results vary depending on the stage and cause of hair loss, individual response, and treatment consistency.

The Wellue Laser Hair Growth Helmet is FDA-cleared to promote hair growth in eligible men and women with androgenetic alopecia.

The cleared indication covers men with Norwood-Hamilton classifications IIa–V and women with Ludwig-Savin classifications I–II, with Fitzpatrick Skin Types I–IV.

If your hair loss is sudden, patchy, caused by scarring, or has not been diagnosed, it is better to determine the underlying cause before starting treatment.

LLLT is intended to support hair follicles that are still capable of producing hair. It may help support cellular activity and the hair-growth cycle in thinning or miniaturizing follicles.

However, it should not be expected to recreate follicles that have been permanently lost or replaced by scar tissue. This is why treatment generally makes more sense while visible thinning hair is still present rather than after an area has been completely bald for a long time.

Not necessarily. What matters more than age alone is the stage and type of hair loss.

If thinning or miniaturized hairs are still visible, there may still be follicles worth supporting. Areas that have been completely bald for a long time are less likely to respond.

For advanced or unexplained hair loss, consider speaking with a dermatologist before starting treatment.

A receding hairline is a common pattern of male androgenetic alopecia. Because the Wellue device is cleared for eligible stages of male pattern hair loss, it may be appropriate for some users experiencing frontal or temporal recession.

Response can vary by area and by how advanced the follicle miniaturization has become.

Crown thinning is another common presentation of androgenetic alopecia. LLLT has been studied in pattern hair loss and may help support hair density where active, miniaturizing follicles remain.

Consistent treatment over several months is usually more meaningful than evaluating the crown after only a few weeks.

A gradually widening part can be a sign of female pattern hair loss. LLLT has been studied in women with androgenetic alopecia, and randomized controlled research using red-light LLLT has shown improved hair counts compared with sham treatment.

Because other conditions can also cause diffuse thinning, women with sudden or unexplained changes should first consider a professional evaluation.

LLLT and minoxidil use different approaches to supporting hair growth and have been studied both separately and in combination.

Clinical literature includes studies of combined LLLT and minoxidil therapy, although results vary and combination therapy should not automatically be assumed to work better for every person.

If you already use minoxidil, continue following its instructions and ask your healthcare professional if you have concerns about combining treatments.

LLLT and finasteride work through different mechanisms.

Finasteride acts on the DHT pathway, while LLLT uses photobiomodulation to support follicle cell activity and hair-growth signaling. Using LLLT does not mean you need to stop finasteride.

Questions about starting, stopping, or changing prescription medication should be discussed with your healthcare provider.

LLLT should not be positioned as a universal replacement for minoxidil or finasteride.

Some people prefer LLLT as a non-drug treatment option, while others use it as part of a broader hair-loss plan. The most appropriate approach depends on the cause and stage of your hair loss, your treatment preferences, and your medical history.

In other words:

LLLT can be used as its own treatment approach, but it does not need to compete with every other hair-loss treatment.

Hair grows slowly, so LLLT is not an overnight treatment.

Visible changes generally require consistent use over several months. Some users may first notice changes in shedding, thickness, or the appearance of thinning areas before more obvious density changes become visible.

A practical expectation is to judge progress over months rather than weeks and use consistent photographs under similar lighting to track changes.

Use the Wellue Laser Hair Growth Helmet for:

30 minutes per session, 3 times per week.

The device's FDA documentation specifies 30-minute treatments three times weekly, with treatments spaced apart.

Using it more frequently or for longer sessions should not be assumed to produce faster or better results.

Pattern hair loss is generally a progressive condition, so the benefits of treatment may require ongoing maintenance.

If treatment is discontinued, the underlying hair-loss process does not necessarily stop. Over time, any gains supported by treatment may diminish.

Think of LLLT as an ongoing hair-maintenance routine rather than a one-time cure.

Temporary changes in shedding can happen for many reasons, including the natural hair-growth cycle, stress, illness, medications, or changes in other hair-loss treatments.

A temporary “LLLT shedding phase” is not as well established as the early shedding sometimes associated with treatments such as minoxidil, so significant or persistent shedding should not automatically be attributed to the laser helmet.

If shedding suddenly increases or becomes patchy, consider speaking with a healthcare professional.

For best light exposure, use the helmet on a clean, dry scalp without hats or other barriers between the laser diodes and your hair.

Heavy styling products or anything that coats the scalp may interfere with direct light exposure, so keeping your normal treatment routine simple and consistent is preferable.

Wellue uses 650nm red laser light, a wavelength commonly used in LLLT devices designed for hair-growth applications.

Red-light wavelengths in this range have been used in randomized clinical studies of androgenetic alopecia, including studies around 655–660nm that reported improvements in hair counts or density.

The wavelength is only one part of treatment design; dose, treatment time, coverage, and consistency also matter.

Both lasers and LEDs can produce red light used for photobiomodulation.

The main physical difference is how the light is emitted: laser diodes produce a more directional beam, while LEDs generally emit light over a broader angle.

That does not mean every laser device automatically works better than every LED device. Treatment effectiveness also depends on wavelength, irradiance, dose, scalp coverage, treatment time, and device design.

Wellue specifically uses a 100% laser configuration rather than a laser-and-LED mix.

Diode count can affect how extensively light sources are distributed across the treatment area, but more diodes alone do not guarantee better hair-growth results.

The important question is whether the combination of:

diode placement + wavelength + light intensity + dose + coverage

delivers an appropriate treatment to the scalp.

Wellue uses 82 dedicated 650nm laser diodes arranged across the helmet to provide broad scalp coverage.

These two measurements describe the light treatment more meaningfully than total device power alone.

3.54 mW/cm² Irradiance
describes how much optical power reaches each square centimeter of the treatment area at a given moment.

6.372 J/cm² Energy Density
describes the total amount of light energy delivered to each square centimeter during one 30-minute treatment.

In simple terms:
Irradiance = how strong the light is.
Energy density = how much light dose you receive over the full session.

A higher number is not automatically better; photobiomodulation depends on delivering an appropriate combination of intensity and treatment time.

LLLT treatment is based on dose, not simply maximum power.

The Wellue treatment schedule combines its light intensity with a 30-minute exposure period to deliver the intended energy density per session.

The FDA-cleared device documentation specifies a schedule of 30 minutes, three times weekly, rather than continuous daily use.

Following the recommended protocol is preferable to increasing treatment time on your own.

Alopecia areata is different from androgenetic alopecia. It is an autoimmune form of hair loss and is not the FDA-cleared indication for the Wellue Laser Hair Growth Helmet.

Research into LLLT for alopecia types other than androgenetic alopecia exists, but the evidence is much less established. A recent systematic review concluded that evidence is strongest for androgenetic alopecia and that more research is needed for other alopecia types.

If you have round or patchy bald spots, consider seeing a dermatologist before using an at-home hair-growth device.

Telogen effluvium often involves increased shedding triggered by factors such as illness, major stress, nutritional problems, hormonal changes, or medications.

The Wellue helmet's FDA-cleared indication is androgenetic alopecia, not telogen effluvium.

Because treating telogen effluvium often depends on identifying and addressing the trigger, unexplained diffuse shedding should be evaluated before assuming LLLT is the appropriate solution.